August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245

by | Sep 2, 2022

August 2022 Top Biopharma Deal Upfront

Sanofi development and commercialization deal with Innovent for SAR408701 and SAR444245

Announced: August 24, 2022

Total Deal Value: $$449.6M

Upfront Cash: n/a

Upfront Equity: $306.6M

Option Payments: n/a

Milestones: $143M dev., reg., and sales milestones

Royalty: Undisclosed

Cost and Profit Split: n/a

The Asset:

Sanofi’s Phase III anti-CEACAM5 antibody-drug conjugate SAR408701 (tusamitamab ravtansine) for the treatment of non-small cell lung cancer (NSCLC) and gastric cancer in China. Additionally, Sanofi and Innovent will co-develop SAR444245, a Phase II non-alpha IL-2 for the treatment of multiple cancers.

Deal Structure:

Development and Commercial License

Partnership Features:

Collaborative Development, No Shared Cost; Co-Development, Shared Dev Cost

The Details:

  • Sanofi granted Innovent exclusive rights to develop and commercialize SAR408701 (tusamitamab ravtansine), a Phase III anti-CEACAM5 antibody-drug conjugate for the treatment of non-small cell lung cancer (NSCLC) and gastric cancer in China. Additionally, Sanofi and Innovent will co-develop SAR444245, a Phase II non-alpha IL-2 for the treatment of multiple cancers.
  • Innovent will be responsible for the clinical development of SAR444245, while Sanofi will be responsible for commercial activities and regulatory approval for both products in China. Sanofi will invest EUR300M (approx. $306.6M) in Innovent up front at HK$42.42 (approx. $5.40) per share in Innovent common stock.
  • Sanofi is eligible for EUR80M (approx. $81.7M) in development milestones and royalties for SAR408701, while Innovent is eligible to receive EUR60M (approx. $61.3M) in development milestones and royalties for SAR444245.

Last Month:

Congrats to Sanofi and Innovent for landing DealForma’s August 2022 Top Biopharma Deal. Last month’s Deal of the Month was Orion – MSD for prostate cancer drug ODM-208. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

28,664

Deal Profiles

18,893

Funding Rounds

32,123

Company Profiles

22,077

Product Profiles

119K+

Clinical Trials

3,967

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.